<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is a metaplastic condition associated with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> and an increased risk for <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Acid plays a significant role in the development and progression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and high dose <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy is often needed </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study is to assess the efficacy of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>, a new potent <z:chebi fb="4" ids="53266">PPI</z:chebi>, on symptom relief and intraesophageal and intragastric acid suppression in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were evaluated by standardized questionnaires and dual sensor 24-h pH monitoring while receiving <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> at a dose (40-80 mg/day) needed for control of symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>Analyses of intraesophageal and intragastric pH profiles were then made </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen patients, mostly men, were studied </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> tolerated <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> (40-80 mg/day) with good symptom control </plain></SENT>
<SENT sid="7" pm="."><plain>Sixty-two percent of patients with BE had abnormal intraesophageal pH profiles despite adequate symptom control on <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> which was associated with significant breakthrough of intraesophageal acid control, particularly at night </plain></SENT>
<SENT sid="8" pm="."><plain>Low nocturnal intragastric pH correlated highly with nocturnal intraesophageal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> (P = 0.004) and there was a relative failure of nocturnal intragastric acid control with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>A high percentage of patients with BE continue to exhibit pathologic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> and low intragastric pH despite <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> for reflux symptom control </plain></SENT>
<SENT sid="10" pm="."><plain>For an antisecretory treatment aimed at chemoprevention of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> to be effective, higher <z:chebi fb="4" ids="53266">PPI</z:chebi> dosing confirmed by pH monitoring may be necessary </plain></SENT>
</text></document>